Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Endometrial Neoplasms 2Mesothelioma, Malignant 1Liver Neoplasms 1FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Doxorubicin 8Cisplatin 5Chemotherapy, Adjuvant 5Thalidomide 4Radiofrequency Ablation 4Neoadjuvant Therapy 4Melphalan 4Cyclophosphamide 4Carboplatin 4tremelimumab 3fludarabine 3aldesleukin 3Sorafenib 3Irinotecan 3Capecitabine 3durvalumab 2carotuximab 2Temozolomide 2Tamoxifen 2Oxaliplatin 2Leucovorin 2Gemcitabine 2Fluorouracil 2Fluorodeoxyglucose F18 2Epirubicin 2Cryosurgery 2Biopsy 2Bevacizumab 2sargramostim 1ropidoxuridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Liver Neoplasms × Megestrol Acetate × Clear all
NCT00041275 2013-09-20

Megestrol in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 3 Completed
300 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡